Michael Liptay to Treatment Outcome
This is a "connection" page, showing publications Michael Liptay has written about Treatment Outcome.
Connection Strength
0.428
-
Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
Score: 0.047
-
Enucleation of a giant esophageal gastrointestinal stromal tumor. Ann Thorac Surg. 2009 May; 87(5):1603-5.
Score: 0.044
-
Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
Score: 0.043
-
Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008 Oct; 144(4):712-7; discussion 717-8.
Score: 0.042
-
Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008 Jan; 33(1):89-94.
Score: 0.040
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.020
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
Score: 0.017
-
Thoracoscopic staging and surgical therapy for esophageal cancer. Chest. 1995 Jun; 107(6 Suppl):218S-223S.
Score: 0.017
-
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
Score: 0.017
-
Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
Score: 0.016
-
Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
Score: 0.015
-
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
Score: 0.014
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.014
-
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
Score: 0.013
-
Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
Score: 0.013
-
Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
Score: 0.012
-
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
Score: 0.012
-
Endobronchial colorectal metastasis versus primary lung cancer: a tale of two sleeve right upper lobectomies. Interact Cardiovasc Thorac Surg. 2009 Aug; 9(2):379-81.
Score: 0.011
-
Utility of silicone esophageal bypass stents in the management of delayed complex esophageal disruptions. Ann Thorac Surg. 2008 Jun; 85(6):1962-7; discussion 1967.
Score: 0.010
-
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
Score: 0.008
-
Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg. 1996 Mar; 61(3):977-82.
Score: 0.004